[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.65.30. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Comment & Response
September 2003

Psoriasis Associated With Rofecoxib

Author Affiliations
  • 1Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago School of Medicine, PO Box 913, Dunedin 9000, New Zealand, (e-mail: david.coulter@stonebow.otago.ac.nz)
Arch Dermatol. 2003;139(9):1223. doi:10.1001/archderm.139.9.1223

Two selective cyclooxygenase type 2 (COX-2) inhibitors, celecoxib (Celebrex) and rofecoxib (Vioxx), are currently being monitored in the New Zealand Intensive Medicines Monitoring Programme (IMMP),1 which undertakes nation-wide prospective observational cohort studies on selected new medicines for a period of 4 to 5 years after the drugs are put on the market. Case details involving a severe exacerbation of psoriasis after the use of rofecoxib were forwarded to the IMMP as part of its normal monitoring process. The prescriber and the patient (a public health physician) were contacted for further information and permission to publish the case.

First Page Preview View Large
First page PDF preview
First page PDF preview
×